efficacy of high Dialysate Magnesium on Parathyroid hormone in ESKD patient dialysis magnesium, parathyroid hormone, FGF23, end-stage renal kidney
Conditions
Interventions
electrolyte dialysate prescription similar in control group except mg in this group increasing from 1 to 2 mEq/L in HD thrice a week , 4 hour per session,standard treatment
electrolyte dialysate
Active Comparator Drug,Placebo Comparator Drug
high dialysate magnesium,standard dialysate magnesium
Sponsors
Bhumiboladulyadej hospital
The Kidney Foundation of Thailand
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.All patients undergoing regular HD 4 hours per session and Thrice a week in center HD for at least 3 months 2.at least 18 years old treatment with maintenance in center HD consent from was done
Exclusion criteria
Exclusion criteria: 1.treatment with peritoneal dialysis 2.previous parathyroidectomy 3.uncontrolled arrythmia disease 4.current treatment with Mg-containing medication or supplements 5. participation in other clinical trial 6. pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| %change PTH level at 12 weeks after end of the intervention %change PTH level | — |
Secondary
| Measure | Time frame |
|---|---|
| serum changes alkaline phosphatase, fibroblast growth factor 23, erythrocyte sedimentation rate, and C-reactive protein levels at 12 weeks after end of the intervention mean change | — |
Countries
Thailand
Contacts
Public ContactAmonrat ekpanithanpong
Bhumiboladulyadej hospital
Outcome results
None listed